Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$58.59 USD
+0.21 (0.36%)
Updated Sep 16, 2025 04:00 PM ET
Pre-Market: $58.75 +0.16 (0.27%) 9:06 AM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PTGX 58.59 +0.21(0.36%)
Will PTGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Other News for PTGX
Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM
Protagonist Therapeutics announces presentations of icotrokinra data
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
H.C. Wainwright Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics announces presentations of icotrokinra data